MF-766

MF-766 is a highly potent, selective and orally active EP4 antagonist with a Ki of 0.23 nM. MF-766 behaves as a full antagonist with an IC50 of 1.4 nM (shifted to 1.8 nM in the presence of 10% HS) in the functional assay. MF-766 can be used for cancer and inflammation diseases research[1][2].

Product Specifications

CAS Number

[1050656-06-8]

Product Name Alternative

3M-852A

UNSPSC

12352005

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/mf-766.html

Purity

99.83

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(O)C1=CC=C(C2(NC(C3=CC=CC4=C3N(CC5=CC=C(C(F)(F)F)C=C5)C=C4)=O)CC2)C=C1

Molecular Formula

C27H21F3N2O3

Molecular Weight

478.46

References & Citations

[1]John Colucci, et al. Discovery of 4-[1-[ ([1-[4- (trifluoromethyl) benzyl]-1H-indol-7-yl]carbonyl) amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain. Bioorg Med Chem Lett|[2]Yun Wang, et al. Combination of EP 4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both